In life sciences market entry, some of the most valuable strategic questions have historically been deprioritized. The time required to factor pipeline intelligence, patent protection timelines, regional pricing and more made them impractical to pursue within typical decision windows.

In pharma, traditional commercial analytics workflows are sequential. The initial point starts from sales data, followed by promotional metrics, then competitive intelligence, and finally, synthesis. Each step takes time, and the process can limit the number and depth of strategic questions asked.¹

Agentic AI helps solve that problem. Using frameworks that provide both speed and deep intelligence, teams can now ask highly nuanced questions and act on key insights faster.²

Why we avoid the hard questions

Questions such as, “Why are we losing market share in France while our promotional investment has increased?” require connecting promotional spend, competitor activity, physician preference shifts and channel saturation all at once, a sophisticated, complex synthesis.¹

Because of this complexity, the answers to those questions used to arrive weeks after the strategic window closed. So people just asked simpler questions instead: “What were last quarter’s sales in Germany?” rather than “How should we sequence our European launch while factoring competitive dynamics, pricing constraints and regional growth trajectories?”

Agentic AI lets us ask deeper questions and expect more nuanced answers. A competitive intelligence report that once took weeks to assemble can now come together in minutes. Gathering insights from disparate data sets used to be a multiweek effort. Now it happens in one sitting.

Decades of insight now accessible on demand

With agentic AI, teams can tap into decades of historical market data across dozens of countries, broken down by quarter. They can pull in pipeline intelligence on thousands of compounds in development, timelines showing when competitors lose patent protection and expert forecasts extending years into the future.

This depth of accessible data enables analyses that were too elongated to justify. Consider a team preparing to launch a new therapy, and one of the first questions is “Which past launches most closely resemble ours?” Finding those comparable products has long meant spending weeks combing through historical launches to identify a handful of relevant precedents. With decades of data now accessible through natural language queries, that same exploration can happen in a single strategy session.

Agentic AI also connects macro-level market trends with granular details in ways traditional workflows couldn’t support. When a user asks how a diabetes therapy is performing across markets, they won’t just get product-level forecasts. They’ll also see regulatory developments and market dynamics that could shape those numbers. That kind of layered insight used to require input from several specialized teams. Now it comes from one query.

The value of continuous intelligence

Speed matters, but the shift from periodic reporting to continuous monitoring may matter more. Traditional competitive intelligence delivers a snapshot of the market at a moment in time. By the time leadership reviews the analysis, the picture may already have changed.

Agentic AI offers a different approach that enables a more dynamic strategy. Teams can configure analyses that refresh as underlying data updates, whether weekly or monthly. When growth projections shift, they can identify the change and take corrective action instead of discovering the variance months later.

Scenario modeling benefits most from this capability, enabling teams to assess how forecast outcomes shift in response to key market‑shaping events, such as competitive launches, policy changes or access dynamics, rather than anchoring decisions to a single baseline projection.¹

Geographic granularity extends this capability by enabling analysts to coherently stitch together information from national markets to regional and global views.¹ A brand manager examining Italian regional performance can situate those insights within the broader European context without waiting for separate analyses from headquarters.

Why purpose-built AI outperforms

Widely available AI tools were built for language. They can summarize documents and generate written content, but they weren’t designed to work with the structured, quantitative data that drives pharmaceutical commercial strategy. Sales figures, promotional spending, prescription volumes and forecast projections don’t behave like text. They require analytical approaches that these tools weren’t trained to handle.

Domain-specific agents close that gap. Trained on pharmaceutical market data, they demonstrate notably higher accuracy on structured data analytics tasks than their mainstream counterparts.³ That accuracy gap matters when the decisions at stake involve billions of dollars in investment.

Building comparable capabilities internally is harder than it looks. It isn’t just a technology problem. It requires domain expertise, proprietary data sets and purpose-built analytical frameworks working in concert. Organizations weighing build-versus-buy decisions increasingly find that the time and resources needed to develop these capabilities in-house delay the very value they’re trying to unlock.

Why human oversight remains essential

Even as analytical capabilities expand, human oversight remains essential.¹ Agentic AI excels at reading data, interpreting patterns and generating recommendations based on the information it can access. What it cannot know are the internal dynamics, marketing plans and strategic priorities that exist within an organization.

The practical guidance is simple: Use these insights to inform human judgment, not replace it. A recommendation based solely on market data may miss considerations that only internal stakeholders understand. The most effective approach combines the breadth and speed of AI analysis with the contextual knowledge that only people can bring.

Decision-making and accountability will ultimately remain with commercial leaders.¹ The goal isn’t to replace analysts but to amplify their capabilities. Freed from manual data gathering, they can focus on interpretation, stakeholder engagement and implementation planning.

Asking the bigger questions

With agentic AI, decision-makers gain the speed and intelligence needed to ask bigger questions and execute with confidence. Teams can model more scenarios, pressure-test assumptions in real time and act on insights while they still matter.

Throughout 2025 and into 2026, leading organizations have embraced this shift. Early adopters who spent last year exploring limited use cases are now moving toward broad implementation. The question is no longer whether these tools will reshape commercial strategy but who will use them first and best.

For commercial leaders navigating complex global launches, the competitive edge belongs to those willing to ask the harder questions. The technology now exists to answer them in time.

References

1. Chaddha K, Jaiswal A. From weeks to minutes: How AI transforms pharmaceutical market entry strategy. Pharmaphorum. December 1, 2025. https://pharmaphorum.com/digital/weeks-minutes-how-ai-transforms-pharmaceutical-market-entry-strategy.
2. Chaddha K, Jaiswal A. Accelerating market entry strategy with agentic AI. IQVIA Blog. October 15, 2025. https://www.iqvia.com/blogs/2025/10/accelerating-market-entry-strategy-with-agentic-ai.
3. Slatko J. Adventures in marketing XVIII. PharmaLive. December 2, 2025. https://www.pharmalive.com/ad-ventures-in-marketing-xviii/.